Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
4.440
+0.050 (1.14%)
Jun 24, 2025, 4:00 PM - Market closed
Pluri Revenue
Pluri had revenue of $427.00K in the quarter ending March 31, 2025, with 501.41% growth. This brings the company's revenue in the last twelve months to $1.03M, up 203.23% year-over-year. In the fiscal year ending June 30, 2024, Pluri had annual revenue of $326.00K with 13.59% growth.
Revenue (ttm)
$1.03M
Revenue Growth
+203.23%
P/S Ratio
24.53
Revenue / Employee
$8,763
Employees
118
Market Cap
34.78M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PLUR News
- 4 weeks ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 2 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 3 months ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 4 months ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 5 months ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 6 months ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 8 months ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 8 months ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire